Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1046-1053

  Chen, Yi Bin ^a   Lane, Andrew A ^b   Logan, Brent R ^c   Zhu, Xiaochun ^c   Akpek, Görgün ^d   Aljurf, Mahmoud D ^e   Artz, Andrew S ^f   Bredeson, Christopher N ^g   Cooke, Kenneth R ^h   Ho, Vincent T ^b   Lazarus, Hillard M ⁱ   Olsson, Richard F ^j   Saber, Wael ^c   McCarthy, Philip L ^k   Pasquini, Marcelo C ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Banner MD Anderson Cancer Center   (United States)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

Autologous transplantation; Idiopathic pneumonia syndrome; Lymphoma

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RITUXIMAB; MYELOABLATIVE AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; GRAFT RECIPIENT; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IDIOPATHIC PNEUMONIA SYNDROME; INCIDENCE; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION; ADOLESCENT; AUTOTRANSPLANTATION; DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PATHOLOGY; PROCEDURES; REGISTER; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84943454051     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.02.005     Document Type: Article

References (34)

1. Colpo A., Hochberg E., Chen Y.B. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. Oncologist 2012, 17:80-90.
2. Moskowitz A.J., Moskowitz C.H. Controversies in the treatment of lymphoma with autologous transplantation. Oncologist 2009, 14:921-929.
3. Nademanee A. Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol 2009, 2:425-442.
4. Fernandez H.F., Escalon M.P., Pereira D., et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplant 2007, 40:505-513.
5. Afessa B., Abdulai R.M., Kremers W.K., et al. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012, 141:442-450.
6. Wong R., Rondon G., Saliba R.M., et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 2003, 31:1157-1163.
7. Benekli M., Smiley S.L., Younis T., et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 2008, 41:613-619.
8. Horning S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997, 89:801-813.
9. Nademanee A., O'Donnell M.R., Snyder D.S., et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995, 85:1381-1390.
10. Puig N., de la Rubia J., Remigia M.J., et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006, 47:1488-1494.
11. Reece D.E., Barnett M.J., Connors J.M., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991, 9:1871-1879.
12. Lane A.A., Armand P., Feng Y., et al. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma 2012, 53:1130-1136.
13. Pasquini M.C., Wang Z., Horowitz M.M., et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010, 87-105.
14. Caballero M.D., Rubio V., Rifon J., et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997, 20:451-458.
15. Wheeler C., Antin J.H., Churchill W.H., et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990, 8:648-656.
16. Ulrickson M., Aldridge J., Kim H.T., et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009, 15:1447-1454.
17. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
18. Vose J.M., Carter S., Burns L.J., et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013, 31:1662-1668.
19. Majhail N.S., Ness K.K., Burns L.J., et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007, 13:1153-1159.
20. Frisk P., Arvidson J., Bratteby L.E., et al. Pulmonary function after autologous bone marrow transplantation in children: a long-term prospective study. Bone Marrow Transplant 2004, 33:645-650.
21. Subira M., Sureda A., Martino R., et al. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen. Haematologica 2000, 85:167-172.
22. Sureda A., Arranz R., Iriondo A., et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001, 19:1395-1404.
23. Caballero M.D., Perez-Simon J.A., Iriondo A., et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003, 14:140-151.
24. Gutierrez-Delgado F., Maloney D.G., Press O.W., et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 2001, 28:455-461.
25. Salar A., Sierra J., Gandarillas M., et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001, 27:405-412.
26. William B.M., Loberiza F.R., Whalen V., et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2013, 13:417-423.
27. Pasquini M.C., Rademacher J.L., Flowers C., et al. Matched pair comparison of busulfan/cyclophosphamide/etoposide (BuCyE) to carmustine/etoposide/cytarabine/melphalan (BEAM) conditioning regimen prior to autologous hematopoietic cell transplantation (autoHCT) for lymphoma. Biol Blood Marrow Transplant 2014, ASBMT abstract.
28. Visani G., Malerba L., Stefani P.M., et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011, 118:3419-3425.
29. Vose J.M., Bierman P.J., Enke C., et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:461-467.
30. Vose J.M., Bierman P.J., Loberiza F.R., et al. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2013, 19:123-128.
31. Nieto Y., Popat U., Anderlini P., et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013, 19:410-417.
32. Bains T., Chen A.I., Lemieux A., et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014, 55:583-587.
33. Krishnan A., Palmer J.M., Tsai N.C., et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant 2012, 18:441-450.
34. William B.M., Allen M.S., Loberiza F.R., et al. Phase I/II study of VELCADE(R)-BEAM (V-BEAM) and autologous hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin lymphoma (NHL), transformed, or mantle cell lymphoma (MCL). Biol Blood Marrow Transplant 2014, 20:536-542.